PURPLE BIOTECHNOLOGY

SOCIETY TO GOVERN SCIENCE

Akila Wijerathna observes how violet biotech protects people and the planet

While red biotechnology develops medicines and green biotechnology engineers crops, purple (or violet) biotechnology occupies a different space entirely. It doesn’t produce a drug, a GMO or an industrial enzyme. Instead, it builds the legal, ethical and philosophical scaffolding that determines whether and how every other branch of biotechnology may be used.

As genetic tools grow more powerful and accessible, this ‘colour’ of biotech has become increasingly central to how societies govern science. So purple biotechnology’s legal dimension centres on three recurring issues: biosafety, biosecurity and intellectual property. And patents and ownership are among the most contested areas.

Can a gene sequence, genetically modified organism or naturally occurring biological compound be patented?

International bodies such as the World Intellectual Property Organization (WIPO) work to reconcile patent law with bioethical concerns. It rewards innovators and recoups research costs without allowing monopolistic control over materials that arguably belong to nature or humanity collectively.

This tension is especially visible in agriculture where patented seed lines can lock farmers into dependency on single suppliers and medicine where patented gene therapies can price lifesaving treatment out of reach of most patients.

Regulatory oversight is the second pillar. National agencies such as Australia’s Office of the Gene Technology Regulator (OGTR), the US Food and Drug Administration (FDA), the US Department of Agriculture (USDA) and the European Medicines Agency (EMA) license and monitor clinical trials, contained research and the environmental release of genetically modified organisms.

These frameworks exist to prevent accidental ecological contamination, ensure informed consent in human trials and create accountability chains if something goes wrong. As gene editing tools such as CRISPR become cheaper and more widespread, regulators face growing pressure to keep pace with a technology that increasingly outstrips the speed of legislation.

If law defines what is permitted, ethics asks what should be. Purple biotechnology draws heavily on the four classical principles of bioethics: auto­nomy, beneficence, non-maleficence and justice.

Human gene editing is the most visible flashpoint.

CRISPR-Cas9 has made germline editing changes that are passed on to future generations technically feasible, and reignited debates that once felt purely speculative. Should parents be allowed to correct a disease causing mutation in an embryo? Where is the line between therapy and enhancement?

A major justice concern runs through all of this. If genetic enhancements become available only to those who can pay, biotechnology could entrench a biological class divide rather than reduce human suffering.

The prospect of designer babies makes this a matter of public concern, rather than simply clinical policy. Animal welfare and ecological balance raise a parallel set of questions.

Engineering animals or plants to produce pharmaceuticals, resist disease or boost yields can deliver real benefits. But it also demands justification against the intrinsic interests of the organisms involved and risk of destabilising ecosystems that have taken millennia to reach equilibrium.

For instance, gene drives could eliminate a disease carrying mosquito population; but their capacity to spread uncontrollably through a wild population makes reversibility – and therefore, ethical caution – a central concern.

Beneath the legal and ethical debates lies a deeper philosophical inquiry: what does it mean to manipulate the fundamental machinery of life? Playing god is the most invoked framing even among secular commentators as it captures a real unease that humans are exercising a degree of control over biological destiny that was previously the exclusive domain of natural selection or that of a creator.

Philosophers examine whether there is a principled distinction between curing and improving, and whether such a distinction can even be maintained once the technical capability exists.

Public perceptions and cultural values shape how societies respond to these questions. Attitudes towards GMOs, cloning or gene therapy vary dramatically across cultures, and are rooted in differing views of what counts as natural.

As biotechnology increasingly blurs the boundary between biological and technological systems, synthetic biology, bio-hybrid materials, engineered microbiomes and even nature itself becomes harder to define. This forces philosophy to keep pace with the laboratory.

Purple biotechnology rarely makes headlines in the way a new vaccine or drought resistant crop does. But it’s arguably the discipline that determines whether those innovations reach society safely, fairly and with public trust intact.

And it provides the tools needed to ensure that this happens.